The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kovacic, N.
Right arrow Articles by Marusic, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kovacic, N.
Right arrow Articles by Marusic, A.
The Journal of Immunology, 2007, 178: 3379-3389.
Copyright © 2007 by The American Association of Immunologists, Inc.

The Fas/Fas Ligand System Inhibits Differentiation of Murine Osteoblasts but Has a Limited Role in Osteoblast and Osteoclast Apoptosis1

Natasa Kovacic2,*, Ivan Kresimir Lukic*, Danka Grcevic{dagger}, Vedran Katavic*, Peter Croucher{ddagger} and Ana Marusic*

* Department of Anatomy, University of Zagreb School of Medicine, Zagreb, Croatia; {dagger} Department of Physiology and Immunology, University of Zagreb School of Medicine, Zagreb, Croatia; and {ddagger} Academic Unit of Bone Biology, University of Sheffield Medical School, Sheffield, United Kingdom

Apoptosis through Fas/Fas ligand (FasL) is an important regulator of immune system homeostasis but its role in bone homeostasis is elusive. We systematically analyzed: 1) the expression of Fas/FasL during osteoblastogenesis and osteoclastogenesis in vitro, 2) the effect of FasL on apoptosis and osteoblastic/osteoclastic differentiation, and 3) osteoblastogenesis and osteoclastogenesis in mice deficient in Fas or FasL. The expression of Fas increased with osteoblastic differentiation. Addition of FasL weakly increased the proportion of apoptotic cells in both osteoclastogenic and osteoblastogenic cultures. In a CFU assay, FasL decreased the proportion of osteoblast colonies but did not affect the total number of colonies, indicating specific inhibitory effect of Fas/FasL on osteoblastic differentiation. The effect depended on the activation of caspase 8 and was specific, as addition of FasL to osteoblastogenic cultures significantly decreased gene expression for runt-related transcription factor 2 (Runx2) required for osteoblastic differentiation. Bone marrow from mice without functional Fas or FasL had similar osteoclastogenic potential as bone marrow from wild-type mice, but generated more osteoblast colonies ex vivo. These colonies had increased expression of the osteoblast genes Runx2, osteopontin, alkaline phosphatase, bone sialoprotein, osteocalcin, and osteoprotegerin. Our results indicate that Fas/FasL system primarily controls osteoblastic differentiation by inhibiting progenitor differentiation and not by inducing apoptosis. During osteoclastogenesis, the Fas/FasL system may have a limited effect on osteoclast progenitor apoptosis. The study suggests that Fas/FasL system plays a key role in osteoblastic differentiation and provides novel insight into the interactions between the immune system and bone.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Welcome Trust (U.K.) Grant CRIGS 073828/Z/03/Z as well as by grants from the Croatian Ministry of Science, Education and Sports (108-1080229-0140, 108-1080229-0142, and 108-1080229-0341).

2 Address correspondence and reprint requests to Dr. Natasa Kovacic, Department of Anatomy, University of Zagreb School of Medicine, Salata 11, Zagreb, Croatia. E-mail address: natasa{at}mef.hr

3 Abbreviations used in this paper: FasL, Fas ligand; AP, alkaline phosphatase; rm, recombinant mouse; RANK, receptor activator of NF-{kappa}B; RANKL, RANK ligand; TRAP, tartrate-resistant acid phosphatase; qPCR, quantitative PCR; PI, propidium iodide; NT, nick translation; OC, osteocalcin; DAPI, 4',6'-diamidino-2-phenylindole; Runx2, runt-related transcription factor 2; BSP, bone sialoprotein; Ct, cycle threshold; OPG, osteoprotegerin; {Delta}Rn, normalized fluorecence reporter signal.




This article has been cited by other articles:


Home page
Endocr. Rev.Home page
J. Lorenzo, M. Horowitz, and Y. Choi
Osteoimmunology: Interactions of the Bone and Immune System
Endocr. Rev., June 1, 2008; 29(4): 403 - 440.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.